References:
  1. Kaptoge S, Pennells L, De Bacquer D, Cooney M, Kavousi M, Stevens G et al. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. The Lancet Global Health. 2019;7(10):e1332-e1345.
  2. Ference B, Graham I, Tokgozoglu L, Catapano A. Impact of Lipids on Cardiovascular Health. Journal of the American College of Cardiology. 2018;72(10):1141-1156.
  3. Yusuf S, Islam S, Chow C, Rangarajan S, Dagenais G, Diaz R et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. The Lancet. 2011;378(9798):1231-1243.
  4. Ference B, Ginsberg H, Graham I, Ray K, Packard C, Bruckert E et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2017;38(32):2459-2472.
  5. Anitschkow N, Chalatow S. Classics in arteriosclerosis research: On experimental cholesterin steatosis and its significance in the origin of some pathological processes, translated by Mary Z. Pelias, 1913. Arteriosclerosis: An Official Journal of the American Heart Association, Inc. 1983;3(2):178-182.
  6. Müller C. Angina Pectoris in Hereditary Xanthomatosis. Archives of Internal Medicine. 1939;64(4):675.
  7. Leary T. Experimental atherosclerosis in the rabbit compared with human (coronary) atherosclerosis. Arch Path 1934;17:453-492.
  8. Nordestgaard B, Chapman M, Humphries S, Ginsberg H, Masana L, Descamps O et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. European Heart Journal. 2013;34(45):3478-3490.
  9. Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. The Lancet. 2007;370(9602):1829-1839.
  10. The Emerging Risk Factors Collaboration*, Di Angelantonio E, Sarwar N. Major Lipids, Apolipoproteins, and Risk of Vascular Disease. JAMA. 2009;302(18):1993.
  11. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet. 2010;376(9753):1670-1681.
  12. Holmes M, Asselbergs F, Palmer T, Drenos F, Lanktree M, Nelson C et al. Mendelian randomization of blood lipids for coronary heart disease. European Heart Journal. 2014;36(9):539-550. [23, 24] using ileal bypass [167 doi 10.1093/annone/mdxl 25 Published 13 April 2017.ccessed. ologies and the vailability AN
  13. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska K, Mewada A et al. Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease. Journal of the American College of Cardiology. 2012;60(25):2631-2639.
  14. Stender S, Tybjærg-Hansen A. Using human genetics to predict the effects and side-effects of drugs. Current Opinion in Lipidology. 2016;27(2):105-111.
  15. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. JAMA. 1984;251(3):351.
  16. Buchwald H, Varco R, Matts J, Long J, Fitch L, Campbell G et al. Effect of Partial Ileal Bypass Surgery on Mortality and Morbidity from Coronary Heart Disease in Patients with Hypercholesterolemia. New England Journal of Medicine. 1990;323(14):946-955.
  17. Boekholdt S, Arsenault B, Mora S, Pedersen T, LaRosa J, Nestel P et al. Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins. JAMA. 2012;307(12):1302.
  18. Cannon C, Blazing M, Giugliano R, McCagg A, White J, Theroux P et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine. 2015;372(25):2387-2397.
  19. Murín J. [Clinical study FOURIER]. Vnitrni Lekarstvi. 2017; 63(6):411-414.
  20. Sinnaeve P, Schwartz G, Wojdyla D, Alings M, Bhatt D, Bittner V et al. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. European Heart Journal. 2019; ehz809.
  21. Sabatine M, Giugliano R, Keech A, Honarpour N, Wiviott S, Murphy S et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine. 2017;376(18):1713-1722.
  22. Nicholls S, Puri R, Anderson T, Ballantyne C, Cho L, Kastelein J et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients. JAMA. 2016;316(22):2373.
  23. Lotufo P, Santos R, Figueiredo R, Pereira A, Mill J, Alvim S et al. Prevalence, awareness, treatment, and control of high low-density lipoprotein cholesterol in Brazil: Baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Journal of Clinical Lipidology. 2016;10(3):568-576.
  24. Berwanger O, Fonseca H, Pinto I, Izar M, Saraiva F, Fonseca F. PO257 Cardiovascular Risk Management In The Primary Prevention of Patients Assisted In the Family Health Programs In the Community In Brazil. Global Heart. 2018;13(4):436.
  25. Lanas F, Serón P, Lanas A. Coronary Heart Disease and Risk Factors in Latin America. Global Heart. 2013;8(4):341-348.
  26. Lanas F, Avezum A, Bautista L, Diaz R, Luna M, Islam S et al. Risk Factors for Acute Myocardial Infarction in Latin America. Circulation. 2007;115(9):1067-1074.
  27. Schoj V, Drake I, Moral M, Goldberg L, Begué C, Olalla J et al. 4° Encuesta Nacional de Factores de Riesgo. Resultados definitivos [Internet]. Msal.gob.ar. 2018 [cited 25 January 2020]. Available from: http://www.msal.gob.ar/images/stories/bes/graficos/0000001622cnt-2019-10_4ta-encuesta-nacional-factores-riesgo.pdf
  28. Mehta R, Zubirán R, Martagón A, Vazquez-Cárdenas A, Segura-Kato Y, Tusié-Luna M et al. The panorama of familial hypercholesterolemia in Latin America: a systematic review. Journal of Lipid Research. 2016;57(12):2115-2129.
  29. Wilemon K, Patel J, Aguilar-Salinas C, Ahmed C, Alkhnifsawi M, Almahmeed W et al. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. JAMA Cardiology. 2020; [Epub ahead of print].
  30. Watts G, Gidding S, Mata P, Pang J, Sullivan D, Yamashita S et al. Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nature Reviews Cardiology. 2020; [Epub ahead of print].
  31. Jones P, Davidson M, Stein E, Bays H, McKenney J, Miller E et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). The American Journal of Cardiology. 2003;92(2):152-160.
  32. Taylor F, Huffman M, Ebrahim S. Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA. 2013;310(22):2451.
  33. Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. Canadian Medical Association Journal. 2011;183(16):E1189-E1202.
  34. Cholesterol Treatment Trialists (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet. 2012;380(9841):581-590.
  35. Cholesterol Treatment Trialists (CTT) Collaborators, Kearney P, Blackwell L, Collins R, Keech A, Simes J. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. The Lancet. 2008;371(9607):117-125.
  36. Cholesterol Treatment Trialists (CTT) Collaborators, Armitage J, Baigent C, Barnes E, Betteridge D, Blackwell L et al. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. The Lancet. 2019;393(10170):407-415.
  37. Giral P, Neumann A, Weill A, Coste J. Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. European Heart Journal. 2019;40(43):3516-3525.
  38. Stroes E, Thompson P, Corsini A, Vladutiu G, Raal F, Ray K et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal. 2015;36(17):1012-1022.
  39. Ridker P, Pradhan A, MacFadyen J, Libby P, Glynn R. Cardiovascular Benefits and Diabetes Risks of Statin Therapy in Primary Prevention: An Analysis From the JUPITER Trial. Journal of Vascular Surgery. 2012;56(6):1809.
  40. Preiss D, Seshasai S, Welsh P, Murphy S, Ho J et al. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy. JAMA. 2011;305(24):2556.
  41. Davis H, Tershakovec A, Tomassini J, Musliner T. Intestinal sterol transporters and cholesterol absorption inhibition. Current Opinion in Lipidology. 2011;22(6):467-478.
  42. Phan B, Dayspring T, Toth P. Ezetimibe therapy: mechanism of action and clinical update. Vascular Health and Risk Management. 2012;8:415-427.
  43. Morrone D, Weintraub W, Toth P, Hanson M, Lowe R, Lin J et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251-261.
  44. Lambert G, Sjouke B, Choque B, Kastelein J, Hovingh G. The PCSK9 decade. Journal of Lipid Research. 2012;53(12):2515-2524.
  45. Seidah N, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nature Reviews Drug Discovery. 2012;11(5):367-383.
  46. Lipinski M, Benedetto U, Escarcega R, Biondi-Zoccai G, Lhermusier T, Baker N et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. European Heart Journal. 2015;37(6):536-545.
  47. Piepoli M, Hoes A, Agewall S, Albus C, Brotons C, Catapano A et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2016;37(29):2315-2381.
  48. Schwartz G, Steg P, Szarek M, Bhatt D, Bittner V, Diaz R et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine. 2018;379(22):2097-2107.
  49. Précoma D, Oliveira G, Simão A, Dutra O, Coelho-Filho O, Izar M et al. Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019. Arquivos Brasileiros de Cardiologia. 2019;113(4) Epub.
  50. Herdy A, López-Jiménez F, Terzic C, Milani M, Stein R, Carvalho T et al. South American Guidelines for Cardiovascular Disease Prevention and Rehabilitation. Arquivos Brasileiros de Cardiologia. 2014;103(2).
  51. Malachias M. Apresentação. Arquivos Brasileiros de Cardiologia. 2016;107(3).
  52. Faludi A, Izar M, Saraiva J, Chacra A, Bianco H, Afiune Neto A et al. Atualização da diretriz brasileira de dislipidemias e prevenção da aterosclerose - 2017. Arquivos Brasileiros de Cardiologia. 2017;109(1).
  53. Pavía AA, Aguilar C. (in press). Consenso de la sociedad mexicana de cardiología y tratamiento de las dislipidemias y ateroesclerosis. Diabetes Hoy.
  54. Stone N, Robinson J, Lichtenstein A, Bairey Merz C, Blum C, Eckel R et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation. 2013;129(25 suppl 2):S1-S45.
  55. Reiner Z, Catapano A, De Backer G, Graham I, Taskinen M, Wiklund O et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal. 2011;32(14):1769-1818.
  56. Hernández S, de Zarate M, Torres Arreola L. Diagnóstico y tratamiento de Dislipidemias (Hipercolesterolemia) en el adulto. Colonia Juárez, Mexico: Instituto Mexicano del Seguro Social; 2016.
  57. Avezum A, Oliveira G, Lanas F, Lopez-Jaramillo P, Diaz R, Miranda J et al. Secondary CV Prevention in South America in a Community Setting. Global Heart. 2017;12(4):305-313.
  58. Murphy A, Palafox B, O’Donnell O, Stuckler D, Perel P, AlHabib K et al. Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study. The Lancet Global Health. 2018;6(3):e292-e301.
  59. Fonseca HAR, Fonseca FA, Pinto IM, Izar MC, Saraiva JF, Berwanger O. Adultos brasileiros que demonstram controle da hipertensão arterial e da diabetes tipo 2 apresentam um controle ineficiente da dislipidemias nas comunidades. Arq Bras Cardiol 2019 113(2 supl.2): 23.
  60. Saraiva J, Cordeiro Mattos A, Saraiva G, Pinto I, Rombaldi A, Kato N et al. P6444Cardiovascular secondary prevention setting and lipid controlu, update data from PINNACLE BRAZIL REGISTRY. European Heart Journal. 2019;40(Supplement_1).
  61. Báscolo E, Houghton N, Del Riego A. Lógicas de transformación de los sistemas de salud en América Latina y resultados en acceso y cobertura de salud. Revista Panamericana de Salud Pública. 2018;42(e126).
  62. Bustamante A, Mendez C. Health Care Privatization in Latin America: Comparing Divergent Privatization Approaches in Chile, Colombia, and Mexico. Journal of Health Politics, Policy and Law. 2014;39(4):841-886.
  63. Healthcare in Latin America and the Caribbean: a democratic challenge [Internet]. openDemocracy. 2016 [cited 26 January 2020]. Available from: https://www.opendemocracy.net/en/democraciaabierta/healthcare-in-latin-america-and-caribbean-democratic-ch/
  64. Atun R, de Andrade L, Almeida G, Cotlear D, Dmytraczenko T, Frenz P et al. Health-system reform and universal health coverage in Latin America. The Lancet. 2015;385(9974):1230-1247.
  65. Rasella D, Harhay M, Pamponet M, Aquino R, Barreto M. Impact of primary health care on mortality from heart and cerebrovascular diseases in Brazil: a nationwide analysis of longitudinal data. BMJ. 2014;349(jul03 5):g4014-g4014.
  66. Salud en las Américas (Resumen: panorama regional y perfiles de país), 2017 Edition [Internet]. Washington, DC: Organización Panamericana de la Salud; 2017 [cited 26 January 2020]. Available from: https://www.paho.org/salud-en-las-americas-2017/wp-content/uploads/2017/09/Print-Version-Spanish.pdf
  67. Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. The Lancet. 2016;387(10013):61-69.
  68. Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, Khatib O et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bulletin of the World Health Organization. 2007;85(4):279-288.
  69. Cunha Garcia G, Rodrigues T. Boletim Saúde e Economia nº 6 (Versão 1.2). Brasilia, Brazil: ANVISA; 2011.
  70. Ribeiro R, Duncan B, Ziegelmann P, Stella S, Vieira J, Restelatto L et al. Cost-Effectiveness of High, Moderate and Low-Dose Statins in the Prevention of Vascular Events in the Brazilian Public Health System. Arquivos Brasileiros de Cardiologia. 2014;104(1):32-43.
  71. Vargas-Pelaez C, Rover M, Soares L, Blatt C, Mantel-Teeuwisse A, Rossi F et al. Judicialization of access to medicines in four Latin American countries: a comparative qualitative analysis. International Journal for Equity in Health. 2019;18(1).
  72. Mitchell A, Simpson R. Statin cost effectiveness in primary prevention: A systematic review of the recent cost-effectiveness literature in the United States. BMC Research Notes. 2012;5:373.
  73. Annemans L, Packard C, Briggs A, Ray K. ‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. European Heart Journal. 2017;39(27):2546-2550.
  74. José Gagliardino J, Arechavaleta R, Goldberg Eliaschewitz F, Iglay K, Brodovicz K, Gonzalez C et al. Dyslipidemia: The untreated metabolic dysfunction in people with type 2 diabetes in Latin America. ARETAEUS study outcomes. Journal of Clinical & Translational Endocrinology. 2019;15:76-80.
  75. Programa Farmácia Popular [Internet]. Ministry of Health Brasil. 2013 [cited 28 November 2019]. Available from: http://www.saude.gov.br/acoes-e-programas/farmacia-popular
  76. Araújo L, Albuquerque K, Kato K, Silveira G, Maciel N, Spósito P et al. Medicamentos genéricos no Brasil: panorama histórico e legislação. Revista Panamericana de Salud Pública. 2010;28(6):480-492.
  77. Kishore S, Blank E, Heller D, Patel A, Peters A, Price M et al. Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases. Journal of the American College of Cardiology. 2018;71(5):564-574.
  78. Años de vida perdidos [Internet]. Organización Panamericana de la Salud. [cited 12 October 2019]. Available from: https://hiss.paho.org/pahosys/pyll.php
  79. Rivera-Andrade A, Luna M. Trends and Heterogeneity of Cardiovascular Disease and Risk Factors Across Latin American and Caribbean Countries. Progress in Cardiovascular Diseases. 2014;57(3):276-285.